Alexis AF, Yamauchi PS, Lin T, Martin G. Efficacy, Safety, and Tolerability of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination in the Treatment of Moderate-to-Severe Plaque Psoriasis in a Hispanic Population: Post Hoc Analysis of Two Phase 3 Randomized Controlled Trials. J of Skin [Internet]. 2019Nov.9 [cited 2024Sep.20];3:S28. Available from: https://dermsquared.com/skin/article/view/755